Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Based on a subgroup analysis by PD-L1 expression from KEYNOTE-811, Merck is working with the US FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
Subscribe To Our Newsletter & Stay Updated
